Cynata completes $913k entitlement offer and locks in $550k placement
Cynata Therapeutics (ASX: CYP) confirmed it raised approximately $912,962 before costs from its fully underwritten pro-rata renounceable entitlement offer (“Entitlement Offer”), first announced on 30 October 2026. The Underwriter, Caravel Securities Pty Ltd (“Carasec”), also advised that firm commitments have been received for a further ~$550,000 before costs via a placement (“Placement”).
When big ASX news breaks, our subscribers know first
Placement terms at a glance
The Placement covers approximately 55 million new, fully paid ordinary shares (“Placement Shares”). Pricing matches the Entitlement Offer, so Placement participants come in on the same terms as existing shareholders who took up the offer.
| Fact | Detail |
|---|---|
| Placement Shares | Approximately 55 million new, fully paid ordinary shares |
| Offer price | $0.01 per Placement Share (same as the Entitlement Offer) |
| Amount to be raised | ~$550,000 before costs |
| Lead manager | Carasec |
Attaching option and fee terms:
- Attaching Option: one free option for every three Placement Shares issued, with the same terms as the Entitlement Options, including an exercise price of $0.02 and an expiry date of 3 May 2029.
- Placement fee: Carasec, as lead manager, will receive a fee equal to 6% of the amount raised under the Placement.
- Placement Fee Options: Carasec will also receive 6,000,000 options to acquire shares, on the same terms as the Attaching Options issued under the Placement.
Board participation
Commitments to the Placement have been received from certain related parties of the Company (or their related entities), putting leadership capital alongside the raise:
- Dr Geoff Brooke (Non-Executive Chairman): $25,000
- Dr Kilian Kelly (Non-Executive Director): $15,000
- Mr Geoff Pocock (nominated for election as a Non-Executive Director at the Company’s forthcoming Annual General Meeting): $20,000
How entitlement offers and placements work
A pro-rata renounceable entitlement offer lets existing shareholders buy new shares in proportion to their current holding. “Renounceable” means they can sell those rights rather than use them. A placement, by contrast, sells new shares to selected investors.
“Underwritten” means the Underwriter commits to ensure the funds are raised. That is why the Entitlement Offer is described as complete.
The weak shareholder take-up in the retail offer is the reason the underwriter’s role mattered, with Caravel absorbing the bulk of the new shares that existing holders left unclaimed.
An attaching option is a free extra issued with shares, giving the holder the right to buy a share later at a set price.
What the funds are for and what happens next
Proceeds of the Placement are intended to give the Company greater flexibility to pursue potential transactions to secure rights to new assets. They will also pay the costs of the offer and provide further working capital, consistent with the use of funds in the replacement Prospectus released on 12 October 2026.
The Board is evaluating future development pathways for the Cymerus™ platform, including seeking opportunities to realise value from the Cymerus™ technology and obtaining rights to new assets.
The search for new assets follows the Phase 2 GvHD trial failure in June, which ended one of the Cymerus platform’s lead clinical programs and left the pipeline thinner.
Two events are flagged ahead:
- General Meeting: shareholder approval will be sought for the Placement (including the issue of Placement Shares and Attaching Options) and the issue of the Placement Fee Options. The General Meeting is to be held as soon as practicable, with details to be communicated in due course.
- Annual General Meeting: Mr Geoff Pocock is nominated for election as a Non-Executive Director at the Company’s forthcoming Annual General Meeting.
Don’t Miss the Next Biotech Breakout
Join 20,000+ investors getting FREE ASX healthcare and biotech news delivered within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to get market-moving news the moment it breaks and stay ahead of the crowd.